Objective:

To evaluate the efficacy and safety of tildrakizumab in patients with moderate-to-severe plaque psoriasis and comorbid diabetes mellitus, highlighting the importance of this subgroup analysis.

Key Findings:

• Tildrakizumab maintained efficacy in achieving PASI 75 and PGA 0/1 responses in patients with diabetes mellitus, with X% achieving PASI 75 compared to Y% in placebo.
• Higher frequency of treatment-emergent adverse events observed in patients with diabetes, particularly those with comorbid obesity, with Z% experiencing serious adverse events.
• Results were consistent with overall findings from reSURFACE 1 and reSURFACE 2 trials.

Interpretation:

Tildrakizumab is effective for treating psoriasis in patients with diabetes, though caution is warranted due to increased adverse events, potentially linked to underlying inflammation.

Limitations:

• Post hoc analysis may introduce bias.
• Lack of long-term safety data specifically for patients with diabetes.
• Findings may not be generalizable to all populations with psoriasis.

Conclusion:

Tildrakizumab is a viable treatment option for moderate-to-severe plaque psoriasis in patients with diabetes, but monitoring for adverse events is essential.